Safe and Fast Radial Hemostasis Using Synergistic Strategies: SAFE & FAST Trial

Patients referred for diagnostic trans-radial cardiac catheterization who meet the inclusion criteria will be randomized into two groups. Group 1 will receive a standard heparin dose (50 U/Kg) with a total compression time of 2 hours using the TR band ® . Group 2 will receive a reduced heparin dose (25 U/Kg) and a compression time of 60 minutes using the VASOBand™, with simultaneous ipsilateral ulnar artery compression.

The study's primary endpoint is a composite of rebound bleeding, post-procedural RAO, and hematoma formation. Radial artery patency will be evaluated using ultrasonography.

With an expected complication rate of 8.2% in Group 1 and 4.5% in Group 2, a sample size of 207 patients per group will provide an 80% power to demonstrate non-inferiority for the treatment group at the alpha 2.5% level. The statistical analysis plan will use descriptive statistics for baseline data and 95% confidence intervals for outcome variables. If non-inferiority is demonstrated, there will be a superiority test performed to examine if Group 2 is superior.

In conclusion, the SAFE & FAST trial intends to establish a safer, quicker protocol for hemostasis after TRA procedures, with the potential to reduce patient recovery time and improve procedure throughput in cardiac catheterization laboratories.

Inclusion criteria

• Patients referred for diagnostic transradial cardiac catheterization
• Age ≥ 18 years
• Ability to provide written informed consent

Exclusion criteria

• Absence of written informed consent
• Patients on long-term systemic anticoagulation therapy for a different indication
• Patients requiring a heparin dose of greater than 50 units per kilogram before, during, or after the procedure for any reason.
• Patients requiring greater than 6 French catheter access